A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
SUMMARY RISK FACTORS Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. “Risk Factors” in this Annual Report on Form 10-K. The principal risks and uncertainties affecting our business include the following: •We have a limited operating history and no history of successfully developing or commercializing any approved antiviral products, which may make it difficult to evaluate the success of our business to date and to assess the prospects for our future viability. •We have incurred significant operating expenses since inception. We expect our expenditures will increase for the foreseeable future. We have no products that have generated any commercial revenue and we may not again achieve or maintain profitability. •We may require substantial additional financing, which may not be available on acceptable terms, or at all.
| Metric | TTM | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | 0 | 351M | 49M |
| Net Income | -147M | 121M | -11M |
| EPS | $-1.77 | $1.37 | $-0.51 |
| Free Cash Flow | 0 | -87M | 297M |
| ROIC | -54.7% | 17.0% | -2.0% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.09 | 0.58 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -165M | 138M | -11M |
| Operating Margin | 0.0% | 39.4% | -22.7% |
| ROE | -46.6% | 17.1% | -2.0% |
| Shares Outstanding | 78M | 88M | 83M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | 49M | 351M | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -11M | 138M | -165M |
| Op. Margin | -22.7% | 39.4% | 0.0% |
| Net Income | -11M | 121M | -147M |
| Net Margin | -22.5% | 34.5% | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -2.0% | 17.0% | -54.7% |
| ROE | -2.0% | 17.1% | -46.6% |
| ROA | -1.3% | 15.7% | -42.9% |
| Cash Flow | |||
| Op. Cash Flow | 297M | -87M | -134M |
| Free Cash Flow | 297M | -87M | 0 |
| Owner Earnings | 289M | -127M | -174M |
| CapEx | 26K | 4K | 0 |
| Maint. CapEx | 19K | 29K | 29K |
| Growth CapEx | 7K | 0 | 0 |
| D&A | 19K | 29K | 29K |
| CapEx/OCF | 0.0% | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 7.5M | 40M | 40M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -77M |
| Cash & Equiv. | N/A | N/A | 77M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | 0.58 | 0.09 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | 548M | 710M | 316M |
| Total Assets | 864M | 773M | 343M |
| Total Liabilities | 316M | 63M | 16M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -65M | 56M | 56M |
| Working Capital | 548M | 716M | 716M |
| Current Assets | 863M | 772M | 772M |
| Current Liabilities | 316M | 57M | 57M |
| Per Share Data | |||
| EPS | -0.51 | 1.37 | -1.77 |
| Owner EPS | 3.48 | -1.43 | -2.23 |
| Book Value | 6.58 | 8.03 | 4.04 |
| Cash Flow/Share | 3.57 | -0.98 | -1.88 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 83.2M | 88.5M | 78.1M |
| Valuation | |||
| P/E Ratio | N/A | 6.6 | -3.3 |
| P/FCF | 11.0 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | 5.9 | 1.1 | 1.4 |
| Price/Sales | 54.0 | 8.9 | N/A |
| FCF Yield | 9.1% | -10.8% | N/A |
| Market Cap | 3.3B | 805M | 453M |
| Avg. Price | 31.58 | 35.26 | 5.80 |
| Year-End Price | 39.09 | 9.10 | 5.80 |
Atea Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 7.5%. At current prices, the estimated annualized return to fair value is -30.0%.
Atea Pharmaceuticals, Inc. (AVIR) has a 5-year average return on invested capital (ROIC) of 7.5%. This is below average and may indicate limited pricing power.
Atea Pharmaceuticals, Inc. (AVIR) has a market capitalization of $453M. It is classified as a small-cap stock.
Atea Pharmaceuticals, Inc. (AVIR) does not currently pay a regular dividend.
Atea Pharmaceuticals, Inc. (AVIR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Atea Pharmaceuticals, Inc. (AVIR) reported annual revenue of $351 million in its most recent fiscal year, based on SEC EDGAR filings.
Atea Pharmaceuticals, Inc. (AVIR) has a net profit margin of 34.5%. This is a strong margin indicating high profitability.
Atea Pharmaceuticals, Inc. (AVIR) generated $-87 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Atea Pharmaceuticals, Inc. (AVIR) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
Atea Pharmaceuticals, Inc. (AVIR) reported earnings per share (EPS) of $1.37 in its most recent fiscal year.
Atea Pharmaceuticals, Inc. (AVIR) has a return on equity (ROE) of 17.1%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 2 years of financial data for Atea Pharmaceuticals, Inc. (AVIR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Atea Pharmaceuticals, Inc. (AVIR) has a book value per share of $8.03, based on its most recent annual SEC filing.